Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer

Expert Opinion on Orphan Drugs

Volumn 2, Issue 12, 2014, Pages 1331-1340

  Krajewska, Jolanta ^a   Jarzab, Barbara ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Differentiated thyroid cancer; E7080; Lenvatinib; Tyrosine kinase inhibitor

Indexed keywords

B RAF KINASE; LENVATINIB; PAZOPANIB; PLACEBO; PROTEIN RET; RADIOACTIVE IODINE; SORAFENIB; VANDETANIB; VASCULOTROPIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DIFFERENTIATED THYROID CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FATIGUE; HUMAN; HYPERTENSION; KIDNEY CANCER; LOSS OF APPETITE; MELANOMA; MESOTHELIOMA; NAUSEA; OVARY CANCER; PANCREAS CANCER; PLASMA CONCENTRATION-TIME CURVE; PROGRESSION FREE SURVIVAL; PROTEINURIA; SARCOMA; SIDE EFFECT; STOMACH CANCER; THROMBOSIS; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; WEIGHT REDUCTION;

EID: 84912119952     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.962514     Document Type: Article

References (64)

1. Cramer JD, Fu P, Harth KC, et al. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery 2010;148(6):1147-52; discussion 1152-3
2. Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013:965212
3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295(18):2164-7
4. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83(12):2638-48
6. Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 2012;22(9):884-9
7. Mihailovic J, Stefanovic L, Malesevic M. Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors. Cancer Biother Radiopharm 2007;22(2):250-5
8. Mazzaferri EL, Jhiang SM. Long-Term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97(5):418-28
9. Ruegemer JJ, Hay ID, Bergstralh EJ, et al. Distant metastases in Differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988;67(3):501-8
10. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167-214
11. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154(6):787-803
12. Jarzab B, Sporny S, Lange D, et al. [Diagnosis and treatment of thyroid cancer - Polish guidelines]. Endokrynol Pol 2010;61(5):518-68
13. Durante C, Haddy N, Baudin E, et al. Long-Term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892-9
14. Sampson E, Brierley JD, Le LW, et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007;110(7):1451-6
15. Pacini F, Ito Y, Luster M, et al. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab 2012;7:541-54
16. Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 2012;166(1):5-11
17. Droz JP, Schlumberger M, Rougier P, et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990;76(5):480-3
18. Matuszczyk A, Petersenn S, Bockisch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008;40(3):210-13
19. Tuttle R, Ball D, Byrd D, et al. NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma. NCCN Guidel.2012;Version 2
20. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11(10):962-72
21. Cohen EW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26(29):4708-13
22. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13(9):897-905
23. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26(29):4714-19
24. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27(10):1675-84
25. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319-28
26. Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459-65
27. Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-Tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor model. Cancer Lett 2013;340(1):97-103
28. Glen H, Mason S, Patel H, et al. E7080, a multi-Targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 2011;11:309
29. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12(2):245-62
30. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13(3):184-99
31. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998;78(10):1379-84
32. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7(7):1932-6
33. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3(6):861-5
34. de la Torre NG, Buley I, Wass JA, Turner HE. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 2006;13(3):931-44
35. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155(6):1967-76
36. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001;86(2):656-8
37. Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23(6):713-22
38. St Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146(3):1145-53
39. Boss DS, Glen H, Beijnen JH, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 2012;106(10):1598-604
40. Yamada K, Yamamoto N, Yamada Y, et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011;17(8):2528-37
41. Shumaker R, Aluri J, Fan J, et al. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. Int J Clin Pharmacol Ther 2014;52(4):284-91
42. Sherman S, Jarzab B, Cabanillas M, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011;29(Suppl):5503
43. Stjepanovic N, Capdevila J. Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics 2014;8:129-39
44. Ball D, Sherman S, Jarzab B, et al. Lenvatinib treatment of advanced RAIrefractory differentiated thyroid cancer (DTC): cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. J Clin Oncol 2012;30(Suppl):5518
45. Schlumberger M, Tahara M, Wirth L, et al. A phase 3, multicenter, double blind, placebo-controlled trial of lenvatinib (E7080) in patients 131Irefractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014;32(Suppl):LBA6008
46. Dadu R, Devine C, Hernandez M, et al. Role of salvage targeted therapy in Differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 2014;99(6):2086-94
47. Schlumberger M, Jarzab B, Cabanillas M, et al. A phase II trial of multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). J Clin Oncol 2012;30(Suppl):5591
48. Molina AM, Hutson TE, Larkin J, et al. A phase 1b clinical trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol 2014;73(1):181-9
49. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96(12):1788-95
50. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGFA expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111(5):707-16
51. Lambrechts D, Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron Disease. Biochim Biophys Acta 2006;1762(11-12):1109-21
52. Qi W, Shen Z, Tang L, Yao Y. Congestive heart failure risk in cancer patients treated with VEGFR-TKIs: a systematic review and meta-Analysis of 36 clinical trials. Br J Clin Pharmacol 2014. [Epub ahead of print
53. Qi WX, Sun YJ, Tang LN, et al. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-Analysis. Crit Rev Oncol Hematol 2014;89(3):394-403
54. Zhang ZF, Wang T, Liu LH, Guo HQ. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-Analysis. PLoS One 2014;9(3):e90135
55. QI WX, Min DL, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-Analysis. Int J Cancer 2013;132(12):2967-74
56. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46(2):439-48
57. Keizer RJ, Gupta A, Mac Gillavry MR, et al. A model of hypertension and proteinuria in cancer patients treated with the anti-Angiogenic drug E7080. J Pharmacokinet Pharmacodyn 2010;37(4):347-63
58. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31(29):3639-46
59. Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-Term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 2013;31(32):4046-53
60. Shumaker RC, Zhou M, Ren M, et al. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers. Cancer Chemother Pharmacol 2014. [Epub ahead of print
61. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134-41
62. Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-Analysis. PLoS One 2012;7(2):e30353
63. Illouz F, Braun D, Briet C, et al. Thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol 2014;171(3):R91-9
64. Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care 2013;7(2):162-7